A Study of Insulin Synthesis and Secretion in Pre-diabetes

Overview

About this study

The purpose of this study is to determine the effect of diabetes-associated variation in TCF7L2 on insulin synthesis and on insulin secretion.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Individuals who previously participated in IRB 11-007525 (n=135)

Exclusion Criteria:

  • Not be taking medications that affect glucose metabolism (to be determined by PI)
  • Have no history of chronic illness or upper gastrointestinal surgery
  • No known active systemic illness 
  • No history of abdominal surgery (other than appendectomy or tubal ligation).

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Adrian Vella, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions